0000886163-16-000130.txt : 20160122 0000886163-16-000130.hdr.sgml : 20160122 20160122192430 ACCESSION NUMBER: 0000886163-16-000130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160120 FILED AS OF DATE: 20160122 DATE AS OF CHANGE: 20160122 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOZARICH JOHN W CENTRAL INDEX KEY: 0001223000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 161357261 MAIL ADDRESS: STREET 1: 10275 SCIENCE CENTER DR CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2016-01-20 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001223000 KOZARICH JOHN W 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 1 0 0 0 Common Stock 2016-01-20 4 M 0 1666.0 59.4 A 51377 D Common Stock 2016-01-20 4 S 0 300.0 92.71 D 51077 D Common Stock 2016-01-20 4 S 0 600.0 93.83 D 50477 D Common Stock 2016-01-20 4 S 0 200.0 94.71 D 50277 D Common Stock 2016-01-20 4 S 0 200.0 96.28 D 50077 D Common Stock 2016-01-20 4 S 0 366.0 97.99 D 49711 D Non-Qualified Stock Option (right to buy) 59.4 2016-01-20 2016-01-20 4 M 0 1666.0 0.0 D 2016-01-31 Common Stock 1666 0 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01,2015, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.24 to $93.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.32, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.51 to $94.91, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.23 to $96.33, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.68 to $98.18, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 1/31/06. By: Charles S. Berkman For: John W. Kozarich 2016-01-22